Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early‐stage Parkinson's disease

7 Sept 2015

Abstract excerpt

The identification of cell-free circulating mitochondrial DNA (ccf-mtDNA) in early-stage Alzheimer's disease (AD) raised the possibility that the same neurodegenerative effect could be observed in Parkinson's disease (PD). Here, and for the first time, we investigated the role of ccf-mtDNA in PD, identifying a significant reduction of ccf-mtDNA in PD patient cerebrospinal fluid (CSF) when compared to controls....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26343811
DOI: 10.1002/ana.24515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early‐stage Parkinson's diseasePMID 26343811Read ↗

Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatmentSemantic proximity Read ↗

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative diseaseSemantic proximity Read ↗

Cell-free mitochondrial DNA in progressive multiple sclerosisSemantic proximity Read ↗

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s DiseaseSemantic proximity Read ↗

Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.Semantic proximity Read ↗

A mitochondrial blood-based patient stratification candidate biomarker for Parkinson’s diseaseSemantic proximity Read ↗

A blood-based marker of mitochondrial DNA damage in Parkinson’s diseaseSemantic proximity Read ↗

Reduced mitochondrial DNA copy number is a biomarker of Parkinson's diseaseSemantic proximity Read ↗

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer diseaseSemantic proximity Read ↗

miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s diseaseSemantic proximity Read ↗

Parkinson's disease--the continuing search for biomarkers.Semantic proximity Read ↗

Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.